Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Early phase clinical trials shows promising results in advanced lung cancer
October 12, 2011
A clinical trial at The Ottawa Hospital Cancer Centre has demonstrated promising results with a new combination therapy for advanced solid cancer, especially lung cancer. The “phase I” study evaluated a new targeted therapy that inhibits the growth of tumour blood vessels (called sunitinib), in combination with the common chemotherapy pemetrexed. Nearly a quarter of the 21 patients with non-small cell lung cancer experienced shrinking of their tumour (partial response), which is more than twice the response rate to either drug on its own, based on previous research. The study was published in
Cancer Chemotherapy and Pharmacology
by Drs. Laura Chow, Derek Jonker and others.
This research was supported by Pfizer Inc. All research at OHRI is also supported by The Ottawa Hospital Foundation.